NEW YORK, March 14, 2017 /PRNewswire/ --
Ahead of today's trading session, Stock-Callers.com shifts focus on fourmajor players in the Drug Manufacturers space: Sanofi SA (NYSE: SNY), Impax Laboratories Inc. (NASDAQ: IPXL), Heron Therapeutics Inc. (NASDAQ: HRTX), and GW Pharmaceuticals PLC (NASDAQ: GWPH). These companies operate in the Healthcare sector, which trended
On Monday, shares in Paris, France headquartered Sanofi recorded a trading volume of 775,188 shares. The stock ended at $43.84, declining 0.16% from the last trading session. The Company's shares have gained 2.67% in the last one month, 10.23% over the previous three months, and 8.41% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 5.37% and 8.83%, respectively. Furthermore, shares of Sanofi, which researches, develops, manufactures, and markets therapeutic solutions, have a Relative Strength Index (RSI) of 61.85.
On March 07th, 2017, Regeneron Pharmaceuticals and Sanofi announced that new Phase-3 data from the Praluent® (alirocumab) Injection clinical trial program will be presented at the American College of Cardiology Scientific Sessions (ACC.17), March 17th-19th, 2017 in Washington, D.C. Key data include presentations on the effects of Praluent across several patient subsets such as diabetes, heterozygous familial hypercholesterolemia (HeFH), and atherosclerotic cardiovascular disease.
On March 09th, 2017, research firm Liberum initiated a 'Hold' rating on the Company's stock. Access our complete research report on SNY for free at:
Hayward, California headquartered Impax Laboratories Inc.'s stock finished yesterday's session 2.26% higher at $9.05 with a total trading volume of 1.55 million shares. The Company's shares are trading below their 50-day moving average by 28.44%. Shares of the Company, which develops, manufactures, and markets bioequivalent pharmaceutical products, have an RSI of 32.93.
On March 08th, 2017, research firm Deutsche Bank upgraded the Company's stock rating from 'Hold' to 'Buy', with a target price of $11 per share.
On March 01st, 2017, Impax reported that total revenues in Q4 2016 decreased 29.7% to $198.4 million compared to $282.1 million in Q4 2015, due primarily to increased competition and/or lower pricing on generic diclofenac sodium gel 3%, metaxalone, fenofibrate and mixed amphetamine salts ER. On a GAAP basis, the Company recorded a per share loss of $3.91 in Q4 2016 compared to income of $0.16 per diluted share in Q4 2015. The complimentary research report on IPXL can be downloaded at:
At the close of trading on Monday, shares in Redwood City, California headquartered Heron Therapeutics Inc. saw a slight decline of 0.34%, ending the day at $14.65. The stock recorded a trading volume of 594,293 shares. The Company's shares have advanced 8.52% in the last one month and 11.83% since the start of this year. The stock is trading 8.00% above its 50-day moving average. Moreover, shares of Heron Therapeutics, which develops products to address unmet medical needs using its proprietary Biochronomer polymer-based drug delivery platform in the US, have an RSI of 55.90.
On February 24th, 2017, Heron Therapeutics announced the inclusion of SUSTOL® (granisetron) extended-release injection as part of the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Antiemesis Version 1.2017. The NCCN has given SUSTOL a Category 1 recommendation, the highest level category of evidence and consensus, for use in the prevention of acute and delayed chemotherapy-induced nausea and vomiting in patients receiving HEC or MEC regimens.
On February 27th, 2017, research firm Needham initiated a 'Buy' rating on the Company's stock, with a target price of $28 per share. Register for free on Stock-Callers.com and get access to the latest PDF format report on HRTX at:
Cambridge, the UK-based GW Pharmaceuticals PLC's shares ended the day 1.39% lower at $123.33. A total volume of 405,107 shares was traded, which was above their three months average volume of 362,730 shares. The stock has gained 4.35% over the previous three months and 10.36% on an YTD basis. The Company's shares are trading 0.84% above their 50-day moving average and 13.12% above their 200-day moving average. Additionally, shares of GW Pharma, which engages in discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant, have an RSI of 44.57.
On March 07th, 2017, GW Pharmaceuticals announced the appointment of Scott Giacobello as Chief Financial Officer on 06th March 2017. Related to this appointment, on 06th March 2017 Adam George, GW's Chief Financial Officer since 2012, became Managing Director - UK, a newly-created executive role with broad leadership responsibilities for UK operations. Download your free research report on GWPH at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Sedentary lifestyle is one that has very little or no physical activity at all, whether at work or ...
Ovarian cancer refers to cancer of ovaries. It is called the "Silent killer", as it is difficult to ...
Schizoaffective disorder is a serious mental disorder in which the individual reflects symptoms ...View All